Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study
Prenatal Diagnosis · 2026-04 · 46 (4) · 533-540
DOI: 10.1002/pd.70104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, online erschienen am 27.02.2026. Verfasst von Hedwig van Hove und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Sotalol, Models, Biological, Tachycardia, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Objective
To establish an optimized sotalol dosing strategy for fetal tachycardia using a pregnancy physiologically based pharmacokinetic (PBPK) model.
Method
A verified PBPK model was developed incorporating pregnancy‐induced physiological changes and placental transfer. Simulations were performed to evaluate current dosing recommendations and alternative dosing scenarios were explored. To avoid maternal dose‐related toxicity (QT‐prolongation), we aimed for maternal concentrations < 2.5 mg/L. Based on neonatal concentration‐effect data, we aimed for fetal C trough concentrations of 0.4–1.0 mg/L.
Results
Model predictions for maternal and fetal plasma concentrations were generally consistent with available maternal and fetal exposure data. Simulations showed that at the maximum oral daily dose of 480 mg, 16% of maternal concentrations exceeded the toxicity threshold, while 90% of fetuses had therapeutic C trough levels. Reducing the daily dose to 400 mg lowered maternal overexposure to 0.1%, with 87% of fetuses still reaching therapeutic levels. Additionally, splitting the 480 mg dose into three administrations per day reduced maternal overexposure to 0.3% and increased fetal target attainment to 95%.
Conclusion
Pregnancy PBPK modeling is a valuable tool for optimizing fetal sotalol therapy. A daily dose not exceeding 400 mg, or dividing daily doses of 240 mg and higher into three administrations, may optimize the balance between predicted fetal efficacy and maternal toxicity risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Neonatal and Pediatric Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Hedwig van Hove
Förderung
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
van Hove, H., van der Heijden, J. E. M., van Uden, A., Gijsen, V. M. G. J., Greupink, R., de Wildt, S. N., & van Drongelen, J. (2026). Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis, 46(4), 533-540. https://doi.org/10.1002/pd.70104
Vancouver
van Hove H, van der Heijden JEM, van Uden A, Gijsen VMGJ, Greupink R, de Wildt SN, et al. Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study. Prenatal Diagnosis. 2026;46(4):533-540. doi:10.1002/pd.70104
BibTeX
@article{vanHove2026,
author = {van Hove, Hedwig and van der Heijden, Joyce E M and van Uden, Anne and Gijsen, Violette M G J and Greupink, Rick and de Wildt, Saskia N and van Drongelen, Joris},
title = {Sotalol Dose Optimization for Fetal Tachycardia: A Pregnancy Physiologically Based Pharmacokinetic Model Study},
journal = {Prenatal Diagnosis},
year = {2026},
volume = {46},
number = {4},
pages = {533--540},
doi = {10.1002/pd.70104}
}
EUVIMED